Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.19.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating expenses:    
Research and development $ 4,107,140 $ 4,735,340
General and administrative 2,254,593 2,248,829
Total operating expenses 6,361,733 6,984,169
Loss from operations (6,361,733) (6,984,169)
Other income (expense):    
Interest income 149,119 152,247
Change in fair value of warrant liabilities 17,799,629 (12,274,559)
Total other income (expense) 17,948,748 (12,122,312)
Net income (loss) $ 11,587,015 $ (19,106,481)
Per share information:    
Net income (loss) per share of common stock, basic and diluted $ 0.15 $ (0.26)
Basic and diluted weighted average shares outstanding 79,409,556 73,656,534